Business Wire

OceanBase Records Over 100% Increase in Number of Customers

13.1.2022 09:59:00 EET | Business Wire | Press release

Share

OceanBase,an enterprise-level distributed relational database provider, announced during this year’s Distributed Database Developer Conference that its database products have been adopted by over 400 customers, which equals to a year-on-year increase of over 100% from 2020 to 2021.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220112006074/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Yang Bing, CEO of OceanBase, speaking during the Distributed Database Developer Conference on January 6, 2022. (Photo: Business Wire)

OceanBase, an Ant Group company, has seen its business expanding rapidly during the past year. So far, a quarter of the top 200 financial institutions in China have chosen OceanBase as a preferred technology provider to upgrade their core IT systems. OceanBase is also serving customers from non-financial service industries such as energy, telecommunication, and transportation. Customers from these sectors contribute to about 35 percent of OceanBase's total revenue.

Meanwhile, OceanBase is exploring the Small and Medium Enterprises (SMEs) market, which now accounts for near 70 percent of its customer base. Regional banks, insurers, security brokers, and wealth management companies have also been partnering with OceanBase and see it as one of the leading database technology providers.

"With its 'product-driven growth' business model, OceanBase aims to make database system management and operation easier and more seamless, " said Yang Bing, CEO of OceanBase. "We look forward to working with partners, customers, developers, and other industry participants to accelerate the development of database technology with continuous technology and product innovations."

"The distributed database is able to handle computing tasks across different nodes, bringing great advantages to dealing with large throughput and group computing," said Michael “Monty” Widenius, founder at MariaDB Foundation and the main author of the original version of the open-source MySQL in the conference. As for open-sourced database products like MariaDB and OceanBase, he commented, “Products and communities will maintain their vitality when they attract tens of millions of users while building healthy businesses."

The rapid development of the internet industry is accelerating the technology innovations of distributed databases that naturally have the ability to expand on a large scale. According to a recent report released by market intelligence provider Gartner, with advanced features including high availability, high scalability, multimodal implementation, supports of hybrid workloads and high compatibility, native distributed databases such as OceanBase are leading the trend of development in database technology, and the CAGR of the global market reaches 16.9 percent.

This year’s Distributed Database Developer Conference was co-hosted by CSDN, Mulan Open-source Community, Open Source China, and OceanBase on January 6. Other speakers participating in the conference included Bruce Momjian, co-founder and core team member of the PostgreSQL Global Development Group, Li Haixiang, the chief architect of Tencent's distributed database TDSQL, and Liu Song, VP of PingCAP.

About OceanBase

Launched in 2010, OceanBase is an enterprise-level distributed relational database developed by Ant Group. OceanBase’s benefits over alternative solutions include strong data consistency, high availability, high performance, low cost, online scalability, and high compatibility with SQL standards and other mainstream relational databases. Its performance has been proven in many Alipay large-scale business scenarios, as well as at the annual 11.11 Global Shopping Festival. In May 2020, OceanBase set the world record for online transaction processing performance, with 707 million transactions per minute in a TPC-C benchmark test. OceanBase was officially registered as a separate company in June 2020.

To learn more, please visit: https://www.oceanbase.com/en

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Inquires
Vick Li Wei
OceanBase
Vick.lw@antgroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye